NCT02254005 2023-10-24
Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
4 trialsNCT02254018 2023-10-24
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Boehringer Ingelheim
Phase 1 Completed
NCT02254031 2023-10-24
Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT02254044 2014-10-01
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
Boehringer Ingelheim
Phase 1 Terminated